Developmental and Epileptic Encephalopathy Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight

DelveInsight's "Developmental and Epileptic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Developmental and Epileptic Encephalopathy, historical and forecasted epidemiology as well as the Developmental and Epileptic Encephalopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Developmental and Epileptic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Developmental and Epileptic Encephalopathy Market Forecast
https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Developmental and Epileptic Encephalopathy Market Report:
• The Developmental and Epileptic Encephalopathy market size across the 7MM was valued at approximately USD 2,100 million in 2023 and is projected to witness robust growth, with a notable CAGR anticipated over the forecast period.
• In May 2025, Researchers from Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital are set to participate in a multicenter clinical trial led by Capsida Biotherapeutics to evaluate an investigational treatment for a severe pediatric epilepsy disorder known as STXBP1-developmental and epileptic encephalopathy (DEE). Additionally, the U.S. Food and Drug Administration has granted clearance for the Investigational New Drug (IND) application for CAP-002, a first-in-class, intravenously administered gene therapy developed by Capsida Biotherapeutics for the treatment of STXBP1-DEE.
• In May 2025, Capsida Biotherapeutics announced that the FDA has cleared the IND for CAP-002, its first-in-class intravenous gene therapy for syntaxin-binding protein 1 developmental and epileptic encephalopathy (STXBP1-DEE). CAP-002 utilizes a proprietary engineered capsid designed to cross the blood-brain barrier while minimizing off-target exposure, and is produced in Capsida's GMP-compliant facility.
• The Developmental and Epileptic Encephalopathies Treatment Market Size in the US was estimated to be nearly USD 1,650 million in 2023, which is expected to increase due to the launch of emerging Developmental and Epileptic Encephalopathies Therapies and label expansion of current therapies.
• Among EU4 and the UK, the highest Developmental and Epileptic Encephalopathies Drugs Market Share was found in Germany which was estimated to nearly 35% of market share in EU4 and the UK in 2023.
• The Developmental and Epileptic Encephalopathies Drugs Market Share of Japan was estimated to be nearly USD 80 million in 2023.
• In 2023, anti-epileptic drug captured the highest Developmental and Epileptic Encephalopathies Treatment Market Size of approximately USD 900 million in the 7MM, followed by EPIDIOLEX/EPIDYOLEX.
• In October 2024, Capsida Biotherapeutics announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to CAP-002, its leading investigational gene therapy for the treatment of Developmental and Epileptic Encephalopathy associated with STXBP1 mutations.
• The total number of Developmental and Epileptic Encephalopathies Prevalence in the 7MM was nearly 284,000 cases in 2023 and are projected to increase during the forecasted period.
• Lennox-Gastaut syndrome (LGS) and Tuberous sclerosis complex (TSC) asscociated epilepsy are the largest contributors to the overall Developmental and Epileptic Encephalopathies pool. The Developmental and Epileptic Encephalopathies prevalence in the United States were nearly 50,000 for LGS and nearly 47,100 for TSC with epilepsy in 2023.
• The total number of cases in EU4 and the UK for Developmental and Epileptic Encephalopathies was estimated to be nearly 104,000 cases in 2023.
• Among EU4 and the UK, the highest number of cases for DEE was found in Germany which was estimated to nearly 34% of cases in EU4 and the UK in 2023.
• The total number of cases in Japan for DEE was estimated to be nearly 34,000 cases in 2023.
• Key Developmental and Epileptic Encephalopathy Companies: Takeda/Ovid Therapeutics, Epygenix, Longboard Pharmaceuticals, Stoke Therapeutics, Neurocrine Biosciences, Praxis Precision Medicines, Zogenix, Inc., Xenon Pharmaceuticals, and others
• Key Developmental and Epileptic Encephalopathy Therapies: Soticlestat(OV935/TAK935), EPX-100, EPX-200, EPX-300, LP352, STK-001, NBI-921352, PRAX-562, Fenfluramine, XEN496, and others
• The Developmental and Epileptic Encephalopathy epidemiology based on gender analyzed that Developmental and Epileptic Encephalopathy is more common in men as compared to women.
• The Developmental and Epileptic Encephalopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Developmental and Epileptic Encephalopathy pipeline products will significantly revolutionize the Developmental and Epileptic Encephalopathy market dynamics.

Developmental and Epileptic Encephalopathy Overview
Developmental and Epileptic Encephalopathy (DEE) represents a cluster of severe epilepsies typified by seizures that frequently resist treatment with drugs. Additionally, these conditions are associated with encephalopathy, a condition denoting substantial developmental delays or, in some cases, regression in developmental abilities.

Get a Free sample for the Developmental and Epileptic Encephalopathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Developmental and Epileptic Encephalopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Developmental and Epileptic Encephalopathy Epidemiology Segmentation:
The Developmental and Epileptic Encephalopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Developmental and Epileptic Encephalopathy
• Prevalent Cases of Developmental and Epileptic Encephalopathy by severity
• Gender-specific Prevalence of Developmental and Epileptic Encephalopathy
• Diagnosed Cases of Episodic and Chronic Developmental and Epileptic Encephalopathy

Download the report to understand which factors are driving Developmental and Epileptic Encephalopathy epidemiology trends @ Developmental and Epileptic Encephalopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Developmental and Epileptic Encephalopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Developmental and Epileptic Encephalopathy market or expected to get launched during the study period. The analysis covers Developmental and Epileptic Encephalopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Developmental and Epileptic Encephalopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Developmental and Epileptic Encephalopathy Therapies and Key Companies
• Soticlestat(OV935/TAK935): Takeda/Ovid Therapeutics
• EPX-100, EPX-200, EPX-300: Epygenix
• LP352: Longboard Pharmaceuticals
• STK-001: Stoke Therapeutics
• NBI-921352: Neurocrine Biosciences
• PRAX-562: Praxis Precision Medicines
• Fenfluramine: Zogenix, Inc.
• XEN496: Xenon Pharmaceuticals

Discover more about therapies set to grab major Developmental and Epileptic Encephalopathy market share @ Developmental and Epileptic Encephalopathy Treatment Landscape
https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Developmental and Epileptic Encephalopathy Market Drivers
• Ztalmy, the first licensed therapy for CDKL5 Deficiency Disorder, was recently approved in the United States, boosting the growth of the DEE market. The vacuum created by a lack of licensed medications will be filled by further R&D advancement.
• With robust uptake, Epidiolex and Fintepla continue to add new prescribers and increase their existing prescriber base.

Developmental and Epileptic Encephalopathy Market Opportunities
• The current competitive scenario of DEE is only restricted to a few therapies. Currently, the market seems to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to grab the potential market space of DEE.
• Emerging drugs with improved seizure control may positively impact the DEE treatment landscape and patients' quality of life.

Scope of the Developmental and Epileptic Encephalopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Developmental and Epileptic Encephalopathy Companies: Takeda/Ovid Therapeutics, Epygenix, Longboard Pharmaceuticals, Stoke Therapeutics, Neurocrine Biosciences, Praxis Precision Medicines, Zogenix, Inc., Xenon Pharmaceuticals, and others
• Key Developmental and Epileptic Encephalopathy Therapies: Soticlestat(OV935/TAK935), EPX-100, EPX-200, EPX-300, LP352, STK-001, NBI-921352, PRAX-562, Fenfluramine, XEN496, and others
• Developmental and Epileptic Encephalopathy Therapeutic Assessment: Developmental and Epileptic Encephalopathy current marketed and Developmental and Epileptic Encephalopathy emerging therapies
• Developmental and Epileptic Encephalopathy Market Dynamics: Developmental and Epileptic Encephalopathy market drivers and Developmental and Epileptic Encephalopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Developmental and Epileptic Encephalopathy Unmet Needs, KOL's views, Analyst's views, Developmental and Epileptic Encephalopathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.